People: Verisante Technology Inc (VRSEF.PK)

VRSEF.PK on OTC Markets Group

0.08USD
23 Dec 2014
Price Change (% chg)

$-0.01 (-14.63%)
Prev Close
$0.08
Open
$0.07
Day's High
$0.08
Day's Low
$0.07
Volume
17,000
Avg. Vol
26,673
52-wk High
$0.25
52-wk Low
$0.07

Search Stocks

Summary

Name Age Since Current Position

Thomas Braun

2010 President, Chief Executive Officer, Chief Business Development Officer, Director

Anna Trinh

2010 Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary

Joseph Biegel

2010 Independent Director

Karen Boodram

49 2009 Independent Director

Christopher Dennis

2009 Independent Director

Jake Thiessen

66 2009 Independent Director

Biographies

Name Description

Thomas Braun

Mr. Thomas A. Braun, BA, LLB, LLM, is President, Chief Executive Officer, Chief Business Development Officer, Director of Verisante Technology, Inc. Mr. Braun holds a Bachelor of Arts from the University of Western Ontario (1988), a Bachelor of Laws from the University of British Columbia (1991) and a Master of Laws from the University of San Francisco (1997). Mr. Braun has been a Member of the State Bar of California since 1997 and a Member of the Law Society of British Columbia since 1999 and practiced corporate law with the law firm of Braun & Company from 1999 to 2009. He is also admitted to practice before the Federal Court for the Northern District of California and the U.S. Ninth Circuit Court of Appeals. Prior to founding the company, Thomas Braun practiced corporate securities law, specializing in representing small high tech public companies. Mr. Braun is also a member of the Advisory Board of the Emerging Communications Technology Institute, an interdisciplinary, inter-faculty research institute based at the University of Toronto.

Anna Trinh

Ms. Anna Trinh is Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary of Verisante Technology, Inc. She has served as the company's VP administration and corporate counsel since the inception of the company in 2006. Ms. Trinh holds a bachelor of commerce degree in finance and an LLB degree from the University of British Columbia. She is also a member of the Law Society of British Columbia, the Canadian Bar Association (B.C.) and the Canadian Corporate Counsel Association.

Joseph Biegel

Mr. Joseph Biegel, BSc, MS, is Independent Director of Verisante Technology, Inc. He holds a Bachelor’s and a Master’s degree in Imaging Science from the Rochester Institute of Technology (1975-1986). Mr. Biegel is the Vice President of Product Management and Marketing for the Medical Imaging Division of McKesson Provider Technologies. He joined McKesson in 2004 and is responsible for developing product strategy and plans for the growing of diagnostic imaging IT solutions from the McKesson Imaging Group.Mr. Biegel has been working in digital imaging for over 27 years, and in diagnostic imaging for 19 years. Prior to joining McKesson, he served as Vice President of Business Development for Agfa Healthcare. Before joining Agfa, he had senior roles in diagnostic imaging product development and marketing at Hewlett-Packard's Medical Products Group, Polaroid Medical Imaging Systems and the DuPont Merck Pharmaceutical Company. Mr. Biegel also was on the faculty of the Rochester Institute of Technology's Center for Imaging Science where he taught courses in imaging and computing and was involved in contract research programs for NASA and other US Government organizations.

Karen Boodram

Ms. Karen Boodram,BSc, MBA, is Independent Director of Verisante Technology, Inc. She holds a Bachelor of Science Degree in Pharmacy and Biochemistry (1984, 1981) from the University of Alberta and a Masters of Business Administration (1999) from the University of Athabasca. Ms. Boodram comes to the company from PI Financial Corp. where she served as a Life Sciences Analyst and has over 20 years of life sciences industry experience including Director of External Affairs for Novartis Pharmaceuticals and several senior management positions (including Manager of Health Economics) for Ciba-Geigy Pharmaceuticals, spanning both the Canadian and European marketplace. Prior to joining PI Financial Corp., Karen led BioManna Consulting where she spearheaded and managed projects for the National Research Council as well as biotechnology, pharmaceutical and medical device companies in North America.

Christopher Dennis

Mr. Christopher John Wesley Dennis is Independent Director of Verisante Technology, Inc. Mr. Dennis holds a Masters of Business Administration from Athabasca University and has served in executive marketing and sales and general management roles for a variety of public and private companies. Mr. Dennis is currently President and CEO of Novadent Inc. a fast-growing network of dental laboratories in the Pacific Northwest, California and Florida. Prior to this, Mr. Dennis was President of Comcare Health services, a private Canadian Company that provides home health care services across Canada with a roster of over 4000 staff. Mr. Dennis has also served as Senior Vice President of Global Commercial Operations for Angiotech Pharmaceuticals Inc. and worked for over 17 years in various divisions of Johnson & Johnson Inc., most recently as the Global President of OrthoNeutrogena based out of Los Angeles. Previous Johnson & Johnson positions included Vice President Marketing and Sales, Janssen Ortho Inc. and President of LifeScan Canada Inc. Mr. Dennis' past board roles have included serving as a board member and on the compensation and audit committees of BioForm Medical Inc., a NASDAQ listed company with head offices in California and as a member of the Board of the First Nations Health Society.

Jake Thiessen

Dr. Jake J. Thiessen, PhD, is Independent Director of Verisante Technology, Inc. He is the Hallman Director, School of Pharmacy, and Director, Health Sciences Campus, University of Waterloo. Jake is a former professor and associate dean at the Leslie Dan Faculty of Pharmacy, University of Toronto. He earned his B.Sc. (Pharm) degree from the University of Manitoba, and went on to complete a M.Sc. at Manitoba and a Ph.D. at the University of California, San Francisco. Jake's area of specialization is pharmacokinetics. His research interests include new approaches in cancer treatment and new molecules to treat patients with iron overload. He has broadened his experience and shared his experience through work with the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health, Health Canada's Scientific Advisory Committee on Bioavailability and Bioequivalence, and the Canadian Council for Accreditation of Pharmacy Programs.

Basic Compensation

Name Fiscal Year Total

Thomas Braun

312,500

Anna Trinh

165,313

Joseph Biegel

--

Karen Boodram

--

Christopher Dennis

--

Jake Thiessen

--
As Of 30 Dec 2012

Options Compensation

Search Stocks